drugset / Trial / NCT00482248
Safety and Tolerability of Omalizumab in Adults and Adolescents With Severe Allergic Asthma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study will assess further the safety and tolerability of long-term treatment with omalizumab by extending omalizumab treatment by 1 year for those patients with allergic asthma who successfully completed study CIGE25011E2.
Timeline
- Start
- 2003-06
- Primary completion
- 2006-06
- Completion
- 2006-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Omalizumab | Monoclonal antibody | — | — |